(RTTNews) - Tuesday, AbbVie reported new Phase 3 AFFIRM data showcasing endoscopic outcomes with subcutaneous Skyrizi in adults with moderately to severely active Crohn's disease.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
AbbVie's Subcutaneous Skyrizi Shows Endoscopic Benefits In Crohn's Diseases
